LEDIFOS is a combination of two hepatitis C virus (HCV) antiviral drugs in a single form. Each single tablet contains ledipasvir and sofosbuvir.
LEDIFOS is a combination of ledipasvir and sofosbuvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover.
Brand Name "Ledifos (Ledipasvir and Sofosbuvir)" medication can be imported and made available on "Named Patient Program (NPP)" treatment in Philippines, Vietnam, Ireland and India. Please contact at +91 9910645395 (Mr. Rakesh) or make an enquiry at info@cancermedicinesnetwork to find the cost price to buy "Ledifos (Ledipasvir and Sofosbuvir)" online and have it delivered where you live. We take guarantee of quality and delivery as per the buyer’s requirements.
Patient, Physcian, distributor/supplier can buy and import Brand Name "Ledifos (Ledipasvir and Sofosbuvir)" from Verve Biosciences, if the drug has not been approved or is not available in your country. Make an enquiry and we will help you calculate the total price to buy "Ledifos (Ledipasvir and Sofosbuvir)" online and have it delivered where you live. From your side, we’ll simply need a prescription from your treating doctor. In some countries we might also need an import license. Our Patient Support team will guide you throughout the process.
Verve Biosciences facilitates import of anti-viral medicines Ledifos (Ledipasvir and Sofosbuvir), Make an enquiry to find the total cost of Ledifos (Ledipasvir and Sofosbuvir) in UAE, Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.